BIIB
Price
$200.05
Change
+$0.09 (+0.05%)
Updated
Jun 12 closing price
Capitalization
29.53B
32 days until earnings call
Intraday BUY SELL Signals
DNLI
Price
$21.66
Change
+$0.64 (+3.04%)
Updated
Jun 12 closing price
Capitalization
3.44B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIIB vs DNLI

Header iconBIIB vs DNLI Comparison
Open Charts BIIB vs DNLIBanner chart's image
BIIB vs DNLI Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7.82B. The market cap for tickers in the group ranges from 658 to 191.7B. AMGN holds the highest valuation in this group at 191.7B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 1%. For the same Theme, the average monthly price growth was 272%, and the average quarterly price growth was 5,865%. ELOX experienced the highest price growth at 118%, while BGMS experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -34%. For the same stocks of the Theme, the average monthly volume growth was -21% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 69
Price Growth Rating: 57
SMR Rating: 85
Profit Risk Rating: 89
Seasonality Score: 23 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 16.49B. The market cap for tickers in the group ranges from 3.44B to 29.53B. BIIB holds the highest valuation in this group at 29.53B. The lowest valued company is DNLI at 3.44B.

High and low price notable news

The average weekly price growth across all stocks in the group was 7%. For the same group, the average monthly price growth was 4%, and the average quarterly price growth was 18%. DNLI experienced the highest price growth at 11%, while BIIB experienced the biggest fall at 2%.

Volume

The average weekly volume growth across all stocks in the group was -3%. For the same stocks of the group, the average monthly volume growth was 20% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 87
P/E Growth Rating: 57
Price Growth Rating: 45
SMR Rating: 89
Profit Risk Rating: 100
Seasonality Score: 17 (-100 ... +100)
VS
BIIB vs. DNLI commentary
Jun 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and DNLI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2026
Stock price -- (BIIB: $200.05 vs. DNLI: $21.66)
Brand notoriety: BIIB: Notable vs. DNLI: Not notable
BIIB represents the Pharmaceuticals: Major, while DNLI is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BIIB: 73% vs. DNLI: 127%
Market capitalization -- BIIB: $29.53B vs. DNLI: $3.44B
BIIB [@Pharmaceuticals: Major] is valued at $29.53B. DNLI’s [@Biotechnology] market capitalization is $3.44B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $1.01T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $112.92B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $186.81B. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BIIB’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, BIIB is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • BIIB’s TA Score: 3 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +2.41% price change this week, while DNLI (@Biotechnology) price change was +10.96% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 16, 2026.

DNLI is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.21% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+0.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($29.5B) has a higher market cap than DNLI($3.44B). DNLI YTD gains are higher at: 31.193 vs. BIIB (13.671). BIIB has higher annual earnings (EBITDA): 2.7B vs. DNLI (-531.76M). BIIB has more cash in the bank: 4.28B vs. DNLI (988M). DNLI has less debt than BIIB: DNLI (34.5M) vs BIIB (6.56B). BIIB has higher revenues than DNLI: BIIB (9.94B) vs DNLI (0).
BIIBDNLIBIIB / DNLI
Capitalization29.5B3.44B858%
EBITDA2.7B-531.76M-508%
Gain YTD13.67131.19344%
P/E Ratio21.51N/A-
Revenue9.94B0-
Total Cash4.28B988M434%
Total Debt6.56B34.5M19,020%
FUNDAMENTALS RATINGS
BIIB vs DNLI: Fundamental Ratings
BIIB
DNLI
OUTLOOK RATING
1..100
6121
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7999
PRICE GROWTH RATING
1..100
4644
P/E GROWTH RATING
1..100
1699
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIIB's Valuation (82) in the Biotechnology industry is in the same range as DNLI (92). This means that BIIB’s stock grew similarly to DNLI’s over the last 12 months.

BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that BIIB’s stock grew similarly to DNLI’s over the last 12 months.

BIIB's SMR Rating (79) in the Biotechnology industry is in the same range as DNLI (99). This means that BIIB’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (44) in the Biotechnology industry is in the same range as BIIB (46). This means that DNLI’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for DNLI (99). This means that BIIB’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBDNLI
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
72%
Bearish Trend 13 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signal:
Gain/Loss:
DNLI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMZA46.350.27
+0.59%
InfraCap MLP ETF
AAXJ117.760.54
+0.46%
iShares MSCI All Country Asia ex Jpn ETF
PCLG21.98-0.14
-0.63%
Polen Focus Growth ETF
EEA10.62-0.12
-1.12%
European Equity Fund (The)
MSTZ8.99-0.61
-6.35%
T-REX 2X Inverse MSTR Daily Target ETF

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.05%
AMGN - BIIB
52%
Loosely correlated
+0.32%
PFE - BIIB
50%
Loosely correlated
+0.15%
AZN - BIIB
49%
Loosely correlated
-1.94%
MRK - BIIB
46%
Loosely correlated
-1.42%
BMY - BIIB
41%
Loosely correlated
+0.40%
More

DNLI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with EDIT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+3.04%
EDIT - DNLI
53%
Loosely correlated
+2.46%
VIR - DNLI
51%
Loosely correlated
+1.06%
BCYC - DNLI
51%
Loosely correlated
-1.22%
VCYT - DNLI
50%
Loosely correlated
-0.19%
PCVX - DNLI
49%
Loosely correlated
+0.36%
More